Vulcan Two sharpens margins as ePharmacy integration gathers pace

What has Vulcan Two announced?

Vulcan Two Group PLC has published an operational and trading update covering the six months ended 30 June 2026.

The central message is that integration work is progressing following the acquisitions of CloudRx, Hyperdrug and Webmed on 19 March 2026. Management is bringing these businesses together while deliberately moving away from some lower-margin, higher credit-risk sales.

That decision is expected to reduce revenue in the near term, but Vulcan Two expects its gross margin percentage to improve. In other words, management is prioritising the quality and profitability of sales rather than chasing volume at any cost.

The update does not disclose revenue, gross profit, operating profit or cash flow figures for the period. Investors are therefore being given a useful operational picture, but not enough financial information to judge the pace of underlying earnings growth.

The original company announcement provides the full detail.

Vulcan Two's key figures

Metric	Position at 30 June 2026 or stated target
Cash balance	Approximately £6.0 million
Revenue paid at point of order	More than 85%
New Leeds distribution facility	22,000 sq ft
Facility expected to be operational	By the end of 2026
Initial launch of new web platform	Expected before the end of Q3 2026
Acquisitions completed	19 March 2026
Revenue and profit figures	Not disclosed

The £6.0 million cash position is an important part of the announcement. Vulcan Two is investing in facilities, systems, staff and integration, so maintaining financial headroom matters.

However, the company has not disclosed net cash after any debt, expected capital expenditure or the overall cost of completing the integration programme.

Integration is moving beyond the planning stage

The operational work appears to be covering the main building blocks needed to create a single ePharmacy platform.

Fit-out work has started at the new 22,000 sq ft distribution facility in Leeds, which remains on schedule to become fully operational by the end of the year. This is intended to provide a central base from which the group can process and dispatch orders more efficiently.

Vulcan Two is also integrating its enterprise resource planning system. An ERP system connects functions such as stock management, purchasing and order fulfilment. Management expects the technology to support same-day or next-day delivery.

This follows the company's previously announced ERP licence agreement for its ePharmacy operations.

There are signs that the acquired operations are already being combined. Webmed's fulfilment has moved to CloudRx, allowing the group to rationalise purchasing, stockholding and dispatch. Vulcan Two is also transferring CloudRx's application programming interface, or API-driven, business-to-business platform into Hyperdrug's veterinary operation.

An API allows different software systems to communicate and exchange information. Applying that capability across the group could make it easier to add customers and process orders without expanding administrative work at the same rate.

A new web platform is also in development, with its initial launch expected before the end of the third quarter. Meanwhile, a naming agency has been appointed to create a unified brand, with the new name expected to be announced within the next few weeks.

Revenue quality is taking priority over volume

Sales growth was described as strong in general healthcare, particularly women's health and attention deficit hyperactivity disorder, or ADHD, medications. This was supported by Vulcan Two's digital prescription platform, which provides prescription fulfilment for clinical customers.

The more revealing part of the update concerns what management has chosen not to pursue.

Vulcan Two has removed a small number of lower-margin customers carrying higher credit risk. These customers mainly operated in the weight-loss sector. Management still regards weight loss as an important category, but says it will be selective rather than pursuing growth that does not meet its profitability requirements.

This will reduce overall revenue in the near term, according to the company. The trade-off is that gross margin percentage is expected to improve.

More than 85% of revenue now comes from customers who pay when ordering. That should support cash conversion, meaning a greater proportion of reported sales is collected promptly as cash. It should also keep exposure to unpaid bills and bad debts relatively low.

For investors, this is a sensible commercial discipline. Headline revenue growth can look attractive, but sales have limited value if margins are thin or customers fail to pay. The drawback is that slower reported revenue could make it harder to assess the underlying growth rate until detailed financial results are published.

Costs will be higher in 2026

The integration programme is not cost-free. Vulcan Two made several appointments earlier than originally planned, while some duplicated costs are being incurred as old and new operations run alongside one another.

As a result, operating costs are expected to be higher in 2026. Management expects costs to reduce in 2027 as historical expenses associated with the acquired businesses fall away.

Key appointments include Keith Butcher as chief financial officer and Declan Lismore as chief pharmacy officer. The group has also expanded its sales and marketing teams to support future growth.

A TUPE consultation is under way to transfer acquired employees to Vulcan Two Ltd. TUPE rules protect employees when a business or undertaking changes owner. The objective is to consolidate the workforce before the end of 2026.

The timing of cost reductions will be worth watching closely. New systems and centralised fulfilment can create efficiencies, but the financial benefit will depend on successful implementation and the group's ability to grow order volumes without rebuilding its cost base.

What looks positive for investors?

The update contains several encouraging points:

• The Leeds facility remains on schedule.
• Systems and fulfilment operations are actively being combined.
• More than 85% of revenue is paid at the point of order.
• Management is removing lower-quality sales rather than prioritising volume.
• The group held approximately £6.0 million of cash at the period end.
• Sales growth was described as strong in selected general healthcare categories.

Collectively, these actions suggest Vulcan Two is trying to build a more repeatable platform rather than simply owning three separate businesses under one listed parent company.

What are the main uncertainties?

The biggest limitation is the absence of detailed financial figures. Revenue, profit, gross margin, operating cash flow and acquisition performance were not disclosed.

Investors also need to consider execution risk. The group is simultaneously opening a distribution facility, introducing an ERP system, launching a web platform, transferring fulfilment, consolidating employees and creating a new brand.

Each initiative may be reasonable on its own, but delivering them together increases operational complexity. Costs are already expected to be higher in 2026, and the announcement does not quantify the increase.

There is also a short-term revenue headwind from removing certain customers. Better margins and lower credit risk would be worthwhile, but future results will need to demonstrate that these benefits outweigh the lost sales.

The next evidence investors need

This update shows credible progress in turning Vulcan Two's March acquisitions into a unified ePharmacy operation. The emphasis on cash collection, margin quality and centralised infrastructure is encouraging.

The next step is financial proof. Investors will want to see whether the new facility and systems open on schedule, whether operating costs reduce in 2027 as planned and whether stronger margins translate into sustainable cash generation.

Until fuller figures arrive, the operational direction looks clearer than the financial outcome. Vulcan Two has explained how it intends to scale the platform. It now needs to show what that platform can earn.